BIIB vs. MRK
Compare and contrast key facts about Biogen Inc. (BIIB) and Merck & Co., Inc. (MRK).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BIIB or MRK.
Key characteristics
BIIB | MRK | |
---|---|---|
YTD Return | -16.48% | 18.89% |
1Y Return | -30.12% | 12.24% |
3Y Return (Ann) | -6.85% | 25.77% |
5Y Return (Ann) | -1.34% | 14.51% |
10Y Return (Ann) | -1.82% | 12.18% |
Sharpe Ratio | -1.32 | 0.79 |
Daily Std Dev | 23.08% | 17.38% |
Max Drawdown | -90.00% | -68.63% |
Current Drawdown | -50.70% | -2.39% |
Fundamentals
BIIB | MRK | |
---|---|---|
Market Cap | $30.42B | $332.33B |
EPS | $8.00 | $0.91 |
PE Ratio | 26.11 | 144.18 |
PEG Ratio | 6.24 | 0.10 |
Revenue (TTM) | $9.66B | $61.40B |
Gross Profit (TTM) | $7.90B | $42.08B |
EBITDA (TTM) | $2.52B | $10.21B |
Correlation
The correlation between BIIB and MRK is 0.28, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
BIIB vs. MRK - Performance Comparison
In the year-to-date period, BIIB achieves a -16.48% return, which is significantly lower than MRK's 18.89% return. Over the past 10 years, BIIB has underperformed MRK with an annualized return of -1.82%, while MRK has yielded a comparatively higher 12.18% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
BIIB vs. MRK - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Biogen Inc. (BIIB) and Merck & Co., Inc. (MRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
BIIB vs. MRK - Dividend Comparison
BIIB has not paid dividends to shareholders, while MRK's dividend yield for the trailing twelve months is around 2.33%.
TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Biogen Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Merck & Co., Inc. | 2.33% | 2.72% | 2.52% | 3.41% | 3.03% | 2.48% | 2.60% | 3.36% | 3.14% | 3.42% | 3.11% | 3.45% |
Drawdowns
BIIB vs. MRK - Drawdown Comparison
The maximum BIIB drawdown since its inception was -90.00%, which is greater than MRK's maximum drawdown of -68.63%. Use the drawdown chart below to compare losses from any high point for BIIB and MRK. For additional features, visit the drawdowns tool.
Volatility
BIIB vs. MRK - Volatility Comparison
Biogen Inc. (BIIB) has a higher volatility of 8.21% compared to Merck & Co., Inc. (MRK) at 4.17%. This indicates that BIIB's price experiences larger fluctuations and is considered to be riskier than MRK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Financials
BIIB vs. MRK - Financials Comparison
This section allows you to compare key financial metrics between Biogen Inc. and Merck & Co., Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities